| Core signaling pathways in human pancreatic cancers revealed by global genomic analyses
| [0003]
|
| Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes
| [0003]
|
| Perspectives in the treatment of pancreatic adenocarcinoma
| [0003]
|
| Inhibition of Ras for cancer treatment: the search continues
| [0003]
|
| Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascade inhibitors: how mutations can result in therapy resistance and how to overcome resistance
| [0003]
|
| Modeling targeted inhibition of MEK and PI3 kinase in human pancreatic cancer
| [0003]
|
| Nature
| [0003]
|
| Mol.Cell. Therapeutics
| [0003]
|
| Stat3/Socs3 activation by IL-6 transsignaling promotes progression of pancreatic intraepithelial neoplasia and development of pancreatic cancer
| [0018]
|
| Myofibroblasts are responsible for the desmoplastic reaction surrounding human pancreatic carcinomas
| [0018]
|
| Mutant p53 drives pancreatic cancer metastasis through cell-autonomous PDGF receptor beta signaling
| [0018]
|
| TORC1 suppression predicts responsiveness to RAF and MEK inhibition in BRAF-mutant melanoma
| [0018]
|
| Coffee EM, Synthetic lethal interaction of combined BCL-XL and MEK inhibition promotes tumor regressions in KRAS mutant cancer models
| [0018]
|
| 1PR1-STAT3 signaling is crucial for myeloid cell colonization at future metastatic sites
| [0018]
|
| STAT3 plays a critical role in KRAS-induced pancreatic tumorigenesis
| [0018]
|
| Pancreatic cancer
| [0019]
|
| Pancreatic cancer-associated stroma production
| [0019]
|
| Complex role for the immune system in initiation and progression of pancreatic cancer
| [0019]
|
| The immune network in pancreatic cancer development and progression
| [0019]
|
| Pro-inflammatory cytokine release by peripheral blood mononuclear cells from patients with advanced pancreatic cancer: relationship to acute phase response and survival
| [0019]
|
| The desmoplastic stroma plays an essential role in the accumulation and modulation of infiltrated immune cells in pancreatic adenocarcinoma
| [0019]
|
| Target therapies in pancreatic carcinoma
| [0019]
|
| Metastatic pancreatic cancer: Is there a light at the end of the tunnel?
| [0019]
|
| Understanding metastasis in pancreatic cancer: a call for new clinical approaches
| [0019]
|
| Inflammatory networks and immune surveillance of pancreatic carcinoma
| [0019]
|
| Dual prognostic significance of tumour-associated macrophages in human pancreatic adenocarcinoma treated or untreated with chemotherapy
| [0019]
|
| Distribution and clinical significance of tumour-associated macrophages in pancreatic ductal adenocarcinoma: a retrospective analysis in China
| [0019]
|
| Tumor-associated macrophages: from mechanisms to therapy
| [0019]
|
| Therapeutic vaccines for cancer: an overview of clinical trials
| [0019]
|
| Combination immunotherapy approaches
| [0019]
|
| Gaudernack G, Long-term follow-up of patients with resected pancreatic cancer following vaccination against mutant K-ras
| [0019]
|
| Understanding local macrophage phenotypes in disease: modulating macrophage function to treat cancer
| [0019]
|
| Adv. Enzyme Regul.
| [0027]
|
| New Avenues in Developmental Cancer Chemotherapy
| [0027]
|
| Molecular Systems Biology
| [0027]
|
| Remington's Pharmaceutical Sciences
| [0076]
|
| Systematic discovery of multicomponent therapeutics
| [0102]
|
| A lentiviral RNAi library for human and mouse genes applied to an arrayed viral high-content screen
| [0103]
|
| Antitumor activity of targeted and cytotoxic agents in murine subcutaneous tumor models correlates with clinical response
| [0107]
|
| R Development Core Team
| [0108]
|
| Dynamic reprogramming of the kinome in response to targeted MEK inhibition in triple-negative breast cancer
| [0120]
|
| Drug resistance via feedback activation of Stat3 in oncogene-addicted cancer cells
| [0120]
|
| STAT3 mediates resistance to MEK inhibitor through microRNA miR-17
| [0120]
|